TORONTO, ON, CANADA (August 16, 2018) – WuXi AppTec Research Service Division (www.wuxiapptec.com), and Cyclica (www.cyclicarx.com) are pleased to announce a multi-phase collaboration to advance drug discovery programs by driving insights into small molecule polypharmacology, while further evolving Cyclica’s biophysics and AI-augmented platform.
Through a multi-phase collaboration, WuXi will leverage and evaluate Cyclica’s cloud-based proteome Ligand Express™ screening platform to investigate the off-target profiles of small molecules, apply Cyclica’s novel and proprietary advanced AI technology to create state of the art predictive models for ADMET properties, and support the testing and optimization of Cyclica’s next generation AI-based de novo drug design technology.
Dr. Dave Madge, Vice President, Research Services Division at WuXi AppTec, commented, “WuXi is on the cutting edge of integrating and leveraging innovative AI solutions in our capability platform, to streamline and create productivity in drug discovery. What makes Cyclica’s value proposition unique is that they offer enabling solutions at various points across the value chain which we believe will help us take further steps in the right direction. We are excited to apply, evaluate, and support the growth of their technologies, and assess how they fit in our overall strategy to advance pre-clinical success.”
Naheed Kurji, President and CEO of Cyclica said, “Over the past two years, we’ve built a strong relationship with the world-class team at WuXi, and we are thrilled to work closely and collaborate with them to advance our shared interests. For Cyclica, this represents an incredible opportunity to continue to drive our innovation plans, while gaining insights and validation from a market leader. This collaboration will enable Cyclica to advance our vision of enabling bench scientists with an intuitive and easy to use cloud-based platform that is built around an integrated network of technologies that support the design, screening, and stratification of better drugs.”
About Cyclica
Cyclica is a Toronto-based biotechnology company that is driving drug discovery by empowering scientists in pharma with an integrated cloud-based and AI-augmented platform that enhances how they design, screen and personalize medicines. To learn more, visit www.cyclicarx.com.
About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.” Please visit: http://www.wuxiapptec.com
Media Inquiries:
Naheed Kurji
President and CEO
Cyclica Inc
naheed.kurji@cyclicarx.com